Parexel: Increased revenue, increased staff in robust Q3

By Zachary Brennan

- Last updated on GMT

Related tags Clinical research services Revenue

Parexel: Increased revenue, increased staff in robust Q3
CRO Parexel announced an uptick in revenue for the third quarter of 2014, as well as a new company record for operating margin.

For the three months ending March 31, 2014, Parexel reported service revenue increased by 8.3% to $492.4m, compared with $454.5m in the same period last year. On a segment by segment basis, service revenue for Q3 of FY 2014 was $373.2 million in Clinical Research Services (CRS), $51.9m in consulting, and $67.3m in the newly branded Parexel Informatics.

Commenting on the results of the quarter, chairman and CEO Josef von Rickenbach, said, “In the third quarter, we delivered revenue in line with guidance, solid operational improvements, earnings that exceeded our expectations, and positive new business results...  We are pleased that the productivity and efficiency-related investments we have made, particularly in the Clinical Research Services business, have continued to pay off​.”

The company added 230 employees in the quarter as the concentration of the company’s top clients decreased when compared to last quarter.

Von Rickenbach continued, “We are experiencing positive momentum in the marketplace, especially with mid and small clients, and we have successfully captured new business from all market segments​.”  

Backlog at the end of March 2014 was $4.93bn, an increase of 9.4% year-over-year.  The reported backlog included gross new business wins in the quarter of $781.6m and cancellations of $208.7m.

Equity analysts sounded upbeat on the conference call. Citi Research analyst Garen Sarafian praised the results, noting that they offer “a high quality beat on the top and bottom line, followed by increasing guidance beyond the beat with one remaining quarter​.”

The company’s acquisition of Heron also contributed approximately $2.5m to revenue in the quarter. Parexel acquired Heron last year​ for $24m.

Future Outlook

Parexel seems to continue to remain upbeat about future prospects as it increased guidance for FY 2014.

Von Rickenbach added that the company is looking to have a higher share of projects in low-cost countries, particularly in India where the company has a strong presence, and especially as the company sees “better results coming out of our early phase units​.”

“The company came out of a period of hyper growth and now we’re seeing more standard growth,”​ Von Rickenbach added, echoing sentiments he previously told us​ in an exclusive interview last June.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more